BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 23, 2004
 |  BioCentury  |  Strategy

Completing the metamorphosis

Morphotek Inc. expects the $26 million it raised in a C round last week to enable it to complete its transition from a toolkit company to a profitable product company. It also expects the round to be its last venture financing.

"Morphotek was founded in 2000 based on morphogenics, and was initially a technology toolbox for pharmaceutical target discovery and product optimization," said CEO Nicholas Nicolaides.

Morphogenics is a process that takes place in culture, and is used to drive the evolution of cells and cellular proteins. In mammalian cells, it is done by inserting a gene into the cell...

Read the full 481 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >